CagriSema vs Tirzepatide
Cagrilintide and semaglutide together in one weekly injection. In the phase 3 REDEFINE 1 trial, people lost 20.4% of body weight over 68 weeks against 3.0% on placebo — 22.7% among those who stayed on treatment [1]. Submitted to the US FDA in December 2025; not approved anywhere yet [9].
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
CagriSema
0.25–2.4 mg
Tirzepatide
5–10 mg
Frequency
CagriSema
Once weekly
Tirzepatide
Once weekly
Administration
CagriSema
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle length
CagriSema
Ongoing — 68-week phase 3 trials, with a 52-week maintenance period after escalation
Tirzepatide
Ongoing/indefinite
Onset speed
CagriSema
Gradual — the full dose is only reached at week 16
Tirzepatide
Moderate (1-2 weeks)
Evidence level
CagriSema
Strong human trials (Phase 3 or FDA approved)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Weight Management
Blood Sugar Control
Appetite Control
Cardiometabolic Risk Factors
Weight Loss
Compound specifications
CagriSema
Molecular formula
Cagrilintide C194H312N54O59S2 · Semaglutide C187H291N45O59
Molecular weight
Two peptides in one pen: ~4409 Da (cagrilintide) + ~4114 Da (semaglutide)
Half-life
Measured together: cagrilintide 159-195 hours, semaglutide 145-165 hours
CAS number
1415456-99-3 (cagrilintide) · 910463-68-2 (semaglutide)
Tirzepatide
Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2
Dosing compared
CagriSema
Subcutaneous
Weeks 1-4
0.25 mg each
Once weekly · Weeks 1-4 — escalation step 1
Both phase 3 REDEFINE trials initiated the fixed-dose pen at 0.25 mg of each drug [1]. Escalation step 1 in the trial protocol, held 4 weeks [7]. Human trials; 2,108 participants took the combination in REDEFINE 1 alone [1].
Weeks 5-8
0.5 mg each
Once weekly · Weeks 5-8 — escalation step 2
Escalation step 2 in the trial protocol, held 4 weeks [7]. The same participants stepped up from 0.25 mg — this is a true titration ladder, confirmed from the protocol and trial methods [1][7].
Weeks 9-12
1.0 mg each
Once weekly · Weeks 9-12 — escalation step 3
Escalation step 3 in the trial protocol, held 4 weeks [7]. Also studied as a maintenance dose in its own right: REIMAGINE 2 carried a cagrilintide-semaglutide 1.0 mg each arm of 595 people with type 2 diabetes for 68 weeks [5].
Weeks 13-16
1.7 mg each
Once weekly · Weeks 13-16 — escalation step 4
Escalation step 4 in the trial protocol, held 4 weeks before the maintenance dose [7].
Week 17
2.4 mg each
Once weekly · Week 17 on — maintenance (52 weeks in phase 3)
The maintenance dose in every phase 3 trial: 2.4 mg of each drug from week 16, held through a 52-week maintenance period in REDEFINE 1 [1]. Investigators could delay escalation or reduce the dose, and participants could stay on a submaximum dose — at week 68, 57.4% of the combination group was on the maximum dose, against 70.9% on semaglutide alone, 82.5% on cagrilintide alone and 70.6% on placebo [1]. Missed doses restarted one step lower per the protocol rules [7].
Tirzepatide
Subcutaneous injection
First 4 weeks
2.5 mg
Once weekly · First 4 weeks
FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
Increase by 2.5 mg after at least 4 weeks at each dose
5-10 mg
Once weekly · Increase by 2.5 mg after at least 4 weeks at each dose
Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
Ongoing maintenance
12.5-15 mg
Once weekly · Ongoing maintenance
15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].
Best suited for
CagriSema
Weight management
About 1 in 5 pounds of body weight lost (20.4%) over 68 weeks against 3.0% on placebo, and 22.7% among people treated as intended — shown in 3,417 adults without diabetes [1].
Type 2 diabetes with excess weight
13.7% weight loss against 3.4% on placebo at 68 weeks, and about 3 in 4 people (73.5%) reached an HbA1c of 6.5% or less against 15.9% on placebo — shown in 1,206 adults [2].
When semaglutide alone is not enough
Head-to-head at the same dose, the combination lost 5.5 percentage points more weight than semaglutide alone and 8.9 more than cagrilintide alone [1]; in 2,713 people with type 2 diabetes it also beat semaglutide 2.4 mg on HbA1c [5].
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].
Side effects
CagriSema
Common
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
Uncommon
- Fatigue and dizziness
- Hair loss (alopecia)
- Gallbladder-related disorders
Serious
- Serious adverse events
- Suspected acute pancreatitis
- Hypoglycaemia with insulin or sulfonylureas
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
CagriSema
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not approved anywhere. Submitted to the US FDA for weight management in December 2025 on the REDEFINE 1 and 2 trials; the type 2 diabetes pathway is still being discussed with regulators.
Safety overview
The safety picture comes from randomised trials with over 4,000 participants exposed to the combination [1][2][3][5]. In REDEFINE 1 (3,417 adults without diabetes), about 4 in 5 people on CagriSema (79.6%) had gastrointestinal events — nausea, vomiting, diarrhoea, constipation or abdominal pain — against about 2 in 5 on placebo (39.9%); most were transient and mild to moderate, peaked during dose escalation, and eased once escalation ended [1]. Any adverse event: 92.3% vs 82.3% on placebo; serious adverse events: about 1 in 10 (9.8%) vs 6.1% on placebo, most commonly hepatobiliary and gastrointestinal disorders; discontinuation of an active drug for adverse events: 5.9% vs 3.5% [1]. Two deaths occurred among the 2,108 people in the combination group; the adjudicated causes were suicide and cancer, and mental-health scores (C-SSRS, PHQ-9) were similar across all four groups throughout the trial [1]. In type 2 diabetes the pattern held: gastrointestinal events 72.5% vs 34.4% on placebo (REDEFINE 2, 1,206 adults) [2]; adverse events 86.9% on the full dose vs 81.2% on semaglutide 2.4 mg alone and 70.5% on placebo (REIMAGINE 2, 2,713 adults) [5]. Heart rate rose slightly (+0.94 beats per minute at week 68, vs +1.17 on semaglutide, -3.31 on cagrilintide and -0.58 on placebo) [1]. In the 32-week phase 2 diabetes trial no level 2 or 3 hypoglycaemia and no fatal events were reported [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 — boxed-warning contraindication for the semaglutide component [7][8]
- Prior serious hypersensitivity to semaglutide, cagrilintide, or their excipients [7][8]
- Pregnancy — trials discontinued treatment on pregnancy [7]
- Not approved anywhere — investigational combination [9]
Tirzepatide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
- History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication
Which is right for you?
Choose CagriSema if...
- Weight loss
- Blood sugar control
- Appetite control
- Metabolic health
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement